Cardiome Pharma Corp. (Formerly Nortran Pharmaceuticals Inc.)
6190 Agronomy Road, 6th Floor
Vancouver
British Columbia
V6T 1Z3
Canada
Tel: 604-677-6905 or 800-330-9928<br>
Fax: 604-677-6915
Website: http://www.cardiome.com/
303 articles about Cardiome Pharma Corp. (Formerly Nortran Pharmaceuticals Inc.)
-
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
4/26/2018
Cardiome Pharma Corp. announced that Mr. David Dean, Chief Business Development Officer of Cardiome, will present at the Bloom Burton & Co. Healthcare Investor Conference.
-
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
4/6/2018
Cardiome Pharma Corp. announced that it has entered into a first amending agreement to its amended and restated term loan agreement with CRG Servicing LLC.
-
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
4/2/2018
Trevyent® is for the treatment of pulmonary arterial hypertension
-
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
3/22/2018
Approval Decision Expected in Third Quarter 2018
-
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
3/20/2018
Cipher Pharmaceuticals and Cardiome Pharma Corp. announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.
-
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
3/13/2018
Cardiome Pharma Corp. reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans.
-
Cardiome Announces Expanded Label for Aggrastat in China Including New STEMI Indication and High Dose Bolus Regimen
1/23/2018
In addition to the expanded indications, the CDE also approved an Aggrastat high dose bolus regimen to be used on both indicated patient populations.
-
Cardiome Announces Strategic Licensing Agreement to Commercialize Aggrastat in Russia
12/12/2017
Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.
-
Cardiome Highlights Partner SteadyMed's Agreement With FDA on Pathway to Trevyent NDA Resubmission
12/11/2017
Cardiome plans to submit regulatory filings for Trevyent in Europe and Canada shortly following SteadyMed's NDA resubmission to the FDA.
-
Cardiome Reports Third Quarter 2017 Financial Results
11/15/2017
Cardiome today reported financial results for the third quarter ended September 30, 2017 and commented on recent accomplishments and plans.
-
Cardiome to Hold Third Quarter 2017 Financial Results Conference Call on November 14
11/7/2017
Cardiome will hold a conference call and webcast at 4:30 p.m. Eastern on that day to discuss the results.
-
Cardiome Announces Expansion of Global Geographic Footprint for Brinavess
11/2/2017
Cardiome today announced the expansion of its geographic presence for Brinavess into the two new key territories of South Africa and Pakistan.
-
Cardiome Announces Commercial Launch of Xydalba in Three New European Geographies
10/30/2017
Cardiome today announced that it has initiated the commercial launch of Xydalba in Sweden, Finland and the Republic of Ireland.
-
Cardiome Announces Agreement With Basilea For Distribution Of Zevtera/Mabelio (Ceftobiprole) In Europe And Israel
9/12/2017
-
Cardiome Release: New Data Presented At European Society of Cardiology Congress 2017 Highlights Clinical Benefit Of BRINAVESS
8/30/2017
-
The FDA Finds Cardiome's Brinavess Data Package Insufficient For NDA Resubmission
8/21/2017
-
Cardiome Pharma Corp. Reports Second Quarter 2017 Financial Results
8/9/2017
-
Cardiome Pharma Corp. To Hold Second Quarter 2017 Financial Results Conference Call On August 8
8/1/2017
-
Cardiome Pharma Corp. Announces Health Canada Approval Of AGGRASTAT High Dose Bolus Regimen
7/17/2017
-
Cardiome Pharma Corp.'s Partner SteadyMed Submits U.S. New Drug Application For TREVYENT For The Treatment Of Pulmonary Arterial Hypertension
7/5/2017